Home > Investor Relations > Financial Results > Latest Results

Latest Results

February 01, 2017

FY2016 Full Year Consolidated Financial Overview

Financial Highlight (IFRS)

Consolidated Statements of Income

(millions of yen, rounded to the nearest one million yen)

Revenues Cost of sales Marketing and distribution Research and development General and administration
491,780 (247,944) (69,770) (85,011) (12,171)
Operating profit Operating profit ratio (%) Profit before taxes Net income Basic Earnings per share (Yen)
76,884 15.6 74,448 54,372 98.12

Consolidated Balance Sheets

(millions of yen, rounded to the nearest one million yen)

Total assets Total non-current assets Total current assets Total non-current liabilities Total current liabilities
806,285 227,525 578,760 (36,128) (123,660)
Capital and reserves attributable to Chugai shareholders Investment on property, plant and equipment (billion yen) Equity ratio attributable to Chugai shareholders (%) Annual dividends per share (yen) Interim dividends per share (yen)
645,508 19.4 80.1 52.00 26.00

Revenues: 491.8 billion JPY (-7.0, -1.4% YoY)

Domestic sales excl. Tamiflu®: increase due to steady growth of new products and mainstay products (+1.7, +0.4%)
Overseas sales: decrease of Actemra® export due to supply price reduction, etc. (-2.7, -3.3%)
Royalties and other operating income: decrease in milestone income (-11.3 -37.2%)

Cost of sales / Operating expenses (Core basis)

Cost of sales: the ratio to sales worsened due to impact of weaker JPY, HIP revision and impact of supply price reduction on Actemra® export, etc. (+1.2% points, from 51.0% to 52.2%)
Operating expenses: overall decrease mainly due to the decrease of marketing and distribution expenses (-4.8, -2.8%)

Profits

IFRS results:  
operating profit  76.9 billion JPY (-9.9, -11.4%)
net income  54.4 billion JPY (-8.0, -12.8%)
Core results:  
operating profit  80.6 billion JPY (-10.1 -11.1%)
net income  56.8 billion JPY (-8.1, -12.5%)
EPS  102.50 JPY (-13.92, -12.0%)

Jan-Dec 2016 Sales excluding Tamiflu®

Core Operating Income Jan-Dec

*Amounts are rounded to the nearest 0.1 billion yen.
Variance and % are calculated based on amounts shown.

To view PDF files,
you will need Adobe® Reader® which is available as a free download.